Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

Chris Bitterli

Dermatology Sales Specialist South West UK
Mob + 44 (0) 7713 386 197
Chris.Bitterli@sanofi.com

BAD 2020 Symposium

Register to view our BAD 2020 Symposium.

Please note that it can take up to 24h to validate your account as an HCP.

Login

Clinical experience of Dupixent (dupilumab) for adults and adolescents with moderate-to-severe atopic dermatitis―what have we learnt so far?

PROF ALAN IRVINE

The role of Type 2 inflammation in atopic dermatitis: emerging insights and clinical implications for a journey beneath the skin

ASSOC PROF MICHAEL ARDERN-JONES

Dupixent for the treatment of adolescents and adults with moderate-to-severe atopic dermatitis: exploring open-label and real-world experience

DR TIM CLAYTON

Treatment options and considerations for managing adolescents with atopic dermatitis: How do I treat a teenager?

AD, atopic dermatitis; BAD, British Association of Dermatologists.

References

  1. DUPIXENT Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8553/smpc. Date accessed: December 2020.